<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693927</url>
  </required_header>
  <id_info>
    <org_study_id>Minitransplant - random</org_study_id>
    <nct_id>NCT00693927</nct_id>
  </id_info>
  <brief_title>Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)</brief_title>
  <official_title>Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized study of allogeneic minitransplantation from HLA-identical family or
      unrelated donors comparing unmanipulated or CD8-depleted PBSC. The conditioning regimen will
      be 2 Gy TBI alone (related donor with low-risk of transplant rejection) or 2 Gy TBI and 3 x
      30 mg/m2 fludarabine (unrelated donor or high risk of transplant rejection). Patients will
      receive a short but intensive immunosuppressive treatment (cyclosporine and mycophenolate
      mofetil) to ensure both graft-versus-host and host-versus-graft tolerance. The rationale for
      using PBSC instead of marrow transplant is to avoid general anesthesia of the donor and to
      minimize the risk of rejection. The rationale for CD8+ depletion is to diminish the risk of
      GVHD after PBSC transplantation or DLI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GVHD in CD8-depleted versus unmanipulated groups</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic GVHD (overall and extensive) in CD8-depleted versus unmanipulated groups.</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection [according to the risk of transplant rejection (see table 1 above)] in CD8-depleted versus unmanipulated groups.</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell (CD3) and myeloid (CD13) chimerism in CD8-depleted versus unmanipulated groups.</measure>
    <time_frame>1-year and then long term</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality and timing of immune reconstitution in CD8-depleted versus unmanipulated groups.</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unmanipulated PBSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD8-Depleted PBSC</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Unmanipulated PBSC after nonmyeloablative conditioning</intervention_name>
    <description>Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).
Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD8-depleted PBSC after nonmyeloablative conditioning</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).</other_name>
    <other_name>CD8-depleted PBSC from HLA-identical sibling or HLA-matched related or unrelated donor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patients

             1.1. Diseases

             Malignant diseases confirmed histologically and not rapidly progressing:

               -  Hematologic malignancies

               -  AML;

               -  ALL;

               -  CML and other myeloproliferative disorders;

               -  MDS;

               -  Multiple myeloma;

               -  CLL;

               -  Non-Hodgkin's lymphoma;

               -  Hodgkin's disease.

               -  Non-hematologic malignancies

               -  Renal cell carcinoma (metastatic).

             1.2. Inclusion criteria

               -  Male or female; female patients must use a reliable contraception method;

               -  Age lower than 70 yrs (family donor) or lower than 65 yrs (unrelated donor);

               -  HIV negative;

               -  No terminal organ failure;

               -  No uncontrolled infection, arrhythmia or hypertension;

               -  Family donor (HLA-identical) or unrelated donor (matched for A-B by low
                  resolution typing and for DRB1-DQB1 by high resolution typing);

               -  No previous radiation therapy precluding the use of 2 Gy TBI

               -  Informed consent given by patient or his/her guardian if of minor age.

             1.3. Clinical situations

               -  Theoretical disease indication for a standard allo-transplant, but not feasible
                  because:

               -  Age &gt; 55 yrs;

               -  Unacceptable end organ performance;

               -  Patient's refusal.

               -  Indication for a standard auto-transplant:

                    -  perform mini-allotransplantation 2-6 months after standard autotransplant.

               -  Not an indication for intensification but a potential candidate for cellular
                  immunotherapy.

          2. Donors

        2.1. Inclusion criteria

          -  Related to the recipient (sibling, parent or child) or unrelated;

          -  Male or female;

          -  Weight &gt; 15 Kg (because of leukapheresis);

          -  HIV negative;

          -  No major contraindication for allogeneic PBSC donation by generally accepted criteria;

          -  Informed consent given by donor or his/her guardian if of minor age.

        2.2. Exclusion criteria

          -  Any condition not fulfilling inclusion criteria;

          -  Unable to undergo leukapheresis because of poor vein access or other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Li√®ge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>September 1, 2011</last_update_submitted>
  <last_update_submitted_qc>September 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic cell transplantation</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Nonmyeloablative</keyword>
  <keyword>CD8-depletion</keyword>
  <keyword>PBSC</keyword>
  <keyword>GVHD</keyword>
  <keyword>Hematological malignancies and renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

